Jubilant Ingrev.
Jubilant Ingrev. Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 4 strong
Not discussed on this call: fundraise.
The short version
The company expects sustained growth momentum driven by Specialty Chemicals and Nutrition segments, alongside a recovery in acetyls. Jubilant Ingrevia has shown steady growth with EBITDA increasing from INR100 crore per quarter three years ago to INR209 crore recently, reflecting confident guidance on overall business performance.
From Jubilant Ingrev.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- The company expects sustained growth momentum driven by Specialty Chemicals and Nutrition segments, alongside a recovery in acetyls.
- Sequential improvement in revenue and EBITDA is anticipated in the coming quarters.
- Fine Chemicals, CDMO, and Nutrition businesses are showing sequential volume growth and portfolio expansion.
- New Niacinamide plant is rapidly ramping up capacity, currently at ~50% volumes, aiming for 70%+ by year-end.
- CDMO business pipeline continues to expand, with over 25 confirmed molecules and a funnel of 100+ molecules with INR3,500+ crore peak revenue potential.
- Volume growth supported by increased volumes in CDMO, Fine Chemicals, and Nutrition segments.
- The company is optimistic about sequential growth partly due to strong acetyls performance.
- Customer engagement and greenfield expansions (e.g., dedicated R&D for semiconductors) support growth visibility.
Profitability & Margins
See what Jubilant Ingrev. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Jubilant Ingrevia is commissioning a new multipurpose plant by the end of the current calendar year, which is expected to strengthen their CDMO and Fine Chemicals growth roadmap (Page 4).
- The company is actively evaluating new growth opportunities across high potential segments such as electronics, semiconductors, cosmetics, and nutrition (Page 7).
- They are building a dedicated R&D and clean room facility at their Greater Noida site targeting the semiconductor and electronics segments (Page 4).
- No other explicit mentions of specific future capital expenditure amounts or new strategic investments were detailed in the provided transcript excerpt.
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Ingrev. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The current confirmed molecules in the CDMO funnel stand at 25, up from 20 in the previous quarter.
- The peak revenue potential from confirmed molecules was previously estimated at around INR1,500 crore, but this has not been updated due to the addition of early-stage molecules whose peak potential is uncertain.
- There are more than 100 molecules in the broader pipeline, but this is dynamic with molecules moving in and out of confirmed and advanced stages.
- The large CDMO contract has a revenue potential of $300 million over 5 years.
- Revenue contribution from confirmed molecules is expected to be at least 25% of the Specialty and Nutrition portfolio.
- There is strong optimism about materialization of orders, but final volume visibility from customers, especially for the large CDMO contract, is awaited and expected within next 1-2 months.
- The order book includes a diversified mix across agro, pharma, personal care, nutrition, and industrial segments.
Jubilant Ingrev. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹86 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Ingrevia Ltd's management said in earlier quarters
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Solar Industries India Ltd (Q1 FY27)
EBITDA margin improvement potential in explosive business to reach mid-teens (18-19% global benchmarks), with combined Solar-BME margins currently at 13-14%…
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Chemicals Ltd (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF Ltd (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
Frequently Asked Questions
What were Jubilant Ingrev. Q1 FY27 results?
The company expects sustained growth momentum driven by Specialty Chemicals and Nutrition segments, alongside a recovery in acetyls. Jubilant Ingrevia has shown steady growth with EBITDA increasing from INR100 crore per quarter three years ago to INR209 crore recently, reflecting confident guidance on overall business performance.
What is Jubilant Ingrev. share price analysis?
Jubilant Ingrev. currently shows a below-average growth signal. The stock trades at a P/E of 36.0 with a market cap of ₹11,442 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Ingrev. planning capital expenditure?
Jubilant Ingrevia is commissioning a new multipurpose plant by the end of the current calendar year, which is expected to strengthen their CDMO and Fine Chemicals growth roadmap (Page 4).
Keep Jubilant Ingrev. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.